CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Aradigm Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Aradigm Corporation
3929 Point Eden Way
Phone: (510) 265-9000p:510 265-9000 Hayward, CA  94545-3720  United States Fax: (510) 265-8878f:510 265-8878

This company ceased filing statements with the SEC on 6/30/2020.
This entity represents the bankrupt estate of the former businesses (assets) of Aradigm Corporation that were not sold to Grifols, S.A. on 3/31/2020.
This company is no longer actively traded on any major stock exchange.

Business Summary
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201812/31/2017YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Interim Principal Executive Officer, Acting Principal Financial Of John M.Siebert 78 3/1/2018 11/6/2006
Chief Medical Officer JuergenFroehlich 59 5/31/2018 11/1/2013
Director EdwinGordon 63 3/6/2018 3/6/2018
Director TheresaMatkovits 51 6/29/2018 6/29/2018
Independent Director Frederick M.Hudson 72 4/1/2014 4/1/2014

Business Names
Business Name
Aradigm Australia Pty Ltd
Aradigm Limited
Aradigm Royalty Financing LLC
ARDM
ARDMQ

General Information
Outstanding Shares: 15,219,793 (As of 9/30/2018)
Shareholders: 61
Stock Exchange: OTC
Federal Tax Id: 943133088
Fax Number: (510) 265-8878
Email Address: investor@aradigm.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023